Patent 7629342 was granted and assigned to Bristol-Myers Squibb on December, 2009 by the United States Patent and Trademark Office.
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II: